52 results
424B5
VKTX
Viking Therapeutics Inc
1 Mar 24
Prospectus supplement for primary offering
4:13pm
. In addition, the compound has been evaluated in chronic toxicity studies of up to 12 months in duration.
In January 2022, we announced the initiation
424B5
VKTX
Viking Therapeutics Inc
27 Feb 24
Prospectus supplement for primary offering
5:21pm
, the compound has been evaluated in chronic toxicity studies of up to 12 months in duration.
In January 2022, we announced the initiation of a Phase 1 single … VK2809 in these completed studies, and overall tolerability remains encouraging. In addition, the compound has been evaluated in chronic toxicity
S-3ASR
3007wcq4e5
26 Jul 23
Automatic shelf registration
5:26pm
PRE 14A
s7qycic
17 Apr 23
Preliminary proxy
5:04pm
424B5
3y5b3
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
sbytu3ln3g8z
29 Mar 23
Prospectus supplement for primary offering
4:01pm
424B5
0xea8zdyfunamn5z
11 Aug 21
Prospectus supplement for primary offering
4:44pm